Anbio Biotechnology (NNNN) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	8.6M	8.6M	8.2M	6.7M	23.5M
Cost of Revenue	1.8M	1.1M	2.3M	3.4M	11.0M
Gross Profit	7.5M	7.5M	5.9M	3.4M	12.6M
Operating Expenses
R&D Expense	325.7K	201.3K	454.2K	134.7K	200.0K
SG&A Expense	2.6M	1.6M	3.4M	1.3M	2.2M
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(1.1M)	—	—	—	—
Total Operating Expenses	1.8M	1.8M	3.9M	1.4M	2.4M
Cost and Expenses	2.9M	2.9M	6.2M	4.8M	13.3M
Operating Income (EBIT)	5.8M	5.8M	2.0M	2.0M	10.2M
Non-Operating
Interest Income	142.0K	142.0K	337.5K	165.3K	42.2K
Interest Expense	—	—	—	—	8.0K
Net Interest Income	142.0K	142.0K	337.5K	165.3K	34.2K
Other Non-Op Income/Expense	635.7K	635.7K	377.5K	292.8K	(184.4K)
Non-Operating Income (excl Interest)	—	—	—	(292.8K)	176.4K
EBT (Pre-Tax Income)	6.4M	6.4M	2.4M	2.3M	10.0M
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	6.4M	6.4M	2.4M	2.3M	10.0M
Earnings from Cont. Ops	6.4M	6.4M	2.4M	2.3M	10.0M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	10.4M	6.4M	2.4M	2.3M	10.0M
Per Share
Basic EPS	$0.24	$0.16	$0.06	$0.02	$0.07
Diluted EPS	$0.24	$0.16	$0.06	$0.01	$0.07
Revenue Per Share	$0.20	$0.20	$0.19	$0.05	$0.16
Shares
Basic Shares Outstanding	43.9M	43.9M	42.3M	143.9M	143.9M
Diluted Shares Outstanding	43.9M	43.9M	42.3M	187.8M	143.9M
Profitability Metrics
EBITDA	6.5M	5.8M	2.0M	2.3M	10.0M
D&A	(2.9M)	—	—	12.1K	6.3K
EBIT	5.8M	5.8M	2.0M	2.3M	10.0M

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025